🚨 𝗧𝗵𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲: Patients with B-cell #lymphoma who relapse after 2 treatments often face relapse or progression again despite CAR-T therapy. 💡 𝗧𝗵𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻: Using QP-Insights, we developed advanced image-based models to predict CAR-T response, overall

🗣️ In his talk at #ECR2024, David Bazaga, Product Lead at Quibim, highlighted critical challenges and innovative solutions in #ProstateCancer diagnosis. Are you curious to learn more about how QP-Prostate is transforming prostate cancer diagnosis? 📲 watch the full video

🧠 Advances in #brain research enable detailed exploration of the brain, improving both research and clinical applications. The development of products like QP-Brain is crucial to precision neuroimaging and, on #WorldBrainDay, we celebrate these advances in #BrainResearch and

🇦🇺 QP-Prostate CAD has been officially approved for use in Australia! We are really proud to announce that, as of today, Quibim's QP-Prostate technology can be used by Australian physicians for #AI-driven lesion detection thanks to algorithms trained with post-biopsy pathology

𝐀𝐠𝐞: 70 years old 𝐏𝐒𝐀 𝐥𝐞𝐯𝐞𝐥: 15 ng/ml, rising kinetic 𝐃𝐑𝐄: Adenoma grade III mpRMI 2 years before PI-RADS 4 in left-lateralized base, biopsy (-) "𝘛𝘩𝘦 𝘴𝘢𝘮𝘦 𝘢𝘨𝘨𝘳𝘦𝘴𝘴𝘪𝘷𝘦 𝘭𝘦𝘴𝘪𝘰𝘯 𝘵𝘩𝘢𝘵 𝘸𝘦 𝘴𝘢𝘸 (𝘢𝘯𝘥 𝘮𝘢𝘵𝘤𝘩𝘦𝘥 𝘸𝘪𝘵𝘩

❓What are the current solutions to make #ProstateCancer testing cheaper and faster? Don't miss our webinar in which Prof. Dr. Punwani, UCL, debunks the latest studies on the subject. ▶️ Available for free on our YouTube channel: lnkd.in/dm63Ykgw

🌟 We are a company dedicated to responsible innovation, aligning our initiatives with the United Nations Sustainable Development Goals (SDGs) to build a future where effective #healthcare is accessible beyond all barriers. Dive into our latest blog to discover more about how we're

In this recent paper, co-authored by Quibim and other leading experts, we explore the strategies used by five major European projects, Primage Project, CHAIMELEON, ProCAncer-I, INCISIVE project and EuCanImage, to manage data de-identification. These are some main takeaways,

New evidence supporting the need to add #AI as the perfect companion to radiologists. Fatigue, feeling hungry, and cyrcadian rythms can introduce overdiagnosis of #ProstateCancer towards the end of the shift. The analysis of 35,000 MRI reports over eight years shows a significant

✅ Improving clinical decision-making, QP-Liver reduces the need for traditionally invasive biopsies, thereby improving #patientcare by providing accurate, non-invasive diagnostics. Full details are disclosed here: quibim.com/newsroom/news-…

In a recent webinar, Prof. Kai Vilanova MD, PhD, analyzed a clinical case initially rated with a PI-RADS score 3. After reviewing the DCE images, he raised the score to 4, but QP-Prostate did not detect any lesions. Further review and biopsy confirmed that QP-Prostate was

🗓️ In two weeks, from September 13-17, our #QuibimTeam will be in Barcelona for the world-leading oncology event: #ESMO2024! 👋🏻 Say hi to booth 526 and discover through our market-approved solution QP-Insights the latest advancements in #oncology, medical imaging, and

Clinicians are sometimes faced with some limitations that lead to misdiagnosis and patient uncertainty. QP-Prostate - the only tool trained with both systematic and targeted biopsies - addresses this problem by increasing sensitivity from 79.8% up to 90.4%. See how QP-Prostate

The path to bringing a new drug to market is challenging: costly trials, lengthy timelines, and the risk of failure due to poor patient selection and limited biomarker #data. 𝗛𝗼𝘄 𝗰𝗮𝗻 𝗤𝗣-𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗵𝗲𝗹𝗽? ➡ Smarter Patient Selection ➡ Non-Invasive Monitoring